Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations
Frontiers in Pharmacology · 05.01.2026 · 16
DOI: 10.3389/fphar.2025.1711196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.01.2026. Verfasst von Seonyoung Byoun und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.
Abstract (Originalsprache)
Introduction
Escitalopram (S-CIT) is commonly prescribed for depression and anxiety in older patients. Previous research has reported that the effect of CYP2C19 polymorphism on S-CIT pharmacokinetics is more pronounced in older adults than in young adults. The current study investigated whether older adults taking S-CIT face a greater risk for CYP2C19-mediated drug-drug interaction (DDI) than young adults.
Methods
Using a physiologically-based pharmacokinetic (PBPK) model, we quantitatively compared the risk of CYP2C19-mediated DDIs in older adults taking S-CIT with any of four CYP2C19 inhibitors (omeprazole, esomeprazole, fluconazole, and fluoxetine). These CYP2C19 inhibitors were selected based on their prevalence of co-administration with S-CIT, as determined by a retrospective analysis of the 2019 Korean National Health Insurance Service senior cohort database. Results and Discussion Our PBPK modeling-based simulations predicted that the extent of DDI incurred by S-CIT would be greater in older adults than in young adults and vary significantly by CYP2C19 phenotypes (extensive, intermediate, and poor metabolizers). Based on the prediction results, we propose CYP2C19 phenotype-guided S-CIT dosing strategies for older adults. Implementing the proposed dosing recommendation may reduce the incidence of potentially inappropriate use of medication and adverse events in older adults prescribed S-CIT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
- College of Pharmacy, Dongguk University-Seoul, Goyang-si, Republic of Korea.
Förderung
- Seoul National University
Zitieren
APA
Byoun, S., Heo, D. G., Lee, M., Lee, R., Li, Y., Lee, J. Y., Hong, E., & Lee, W. (2026). Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1711196
Vancouver
Byoun S, Heo DG, Lee M, Lee R, Li Y, Lee JY, et al. Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1711196
BibTeX
@article{Byoun2026,
author = {Byoun, Seonyoung and Heo, Dong-Gyu and Lee, Minsoo and Lee, Ryunghwa and Li, Yuanyuan and Lee, Ju-Yeun and Hong, Eunjin and Lee, Wooin},
title = {Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {16},
doi = {10.3389/fphar.2025.1711196}
}
EUVIMED